摘要:
The invention relates to a method for the purification of a body fluid comprising antibodies corresponding to whole human or animal blood or to a product derived from human or animal blood, in which the body fluid is brought into contact with at least one substrate comprising a solid phase to which molecules of at least one oligosaccharide that can bind to one or more antibodies present in the body fluid are covalently grafted, such as to capture at least a portion of the antibodies present in the body fluid by means of bond(s) with at least some of the oligosaccharide molecules grafted to the solid phase. The method is characterised in that the solid phase carries free aldehyde (-CHO) functions.
摘要:
The invention relates to a substrate for the purification of a body fluid, comprising a solid phase to which molecules of at least one oligosaccharide that can bind to one or more antibodies are covalently grafted, said solid phase carrying free aldehyde (-CHO) functions. The invention also relates to a method for producing such a substrate, the use of such a substrate in stabilising the antibody/oligosaccharide bond, and a method for purifying a body fluid, in which the body fluid is brought into contact with at least one substrate according to the invention, such as to capture antibodies present in the body fluid by means of bond(s) with at least some of the oligosaccharide molecules grafted to the solid phase.
摘要:
The present invention relates to polysaccharides selected from sulphated arabinogalactans, apiogalacturonans and sulphated heteroglycans intended to be used as a drug for the preventive or curative treatment of an influenza virus, as well as to the pharmaceutical compositions including, in particular in combination with at least one pharmaceutically acceptable carrier: either an extract of Codium fragile, including sulphated arabinogalactans, or an extract of Zostera marina or Lemna minor, including apiogalacturonans, or an extract of Caulerpa racemosa, including sulphated heteroglycans.
摘要:
The invention relates to an eliciting composition that comprises a synergic mixture of at least one xyloglucane derivative and at least one polyol.